<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133950</url>
  </required_header>
  <id_info>
    <org_study_id>B.U.N. 143201420647</org_study_id>
    <nct_id>NCT02133950</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Segmentation of PGD Treatment</brief_title>
  <official_title>A Single Centre Randomised Controlled Study Into the Segmentation of Preimplantation Genetic Diagnosis (PGD) Treatment by Comparing Cumulative Pregnancy Rates Following Cryopreservation of All Genetically Transferable Embryos After PGD, Compared to Fresh Embryo Transfer Cumulative With Frozen Embryo Transfer of Genetically Transferable Embryos.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single centre observational study into the segmentation of preimplantation genetic
      diagnosis (PGD) treatment by comparing cumulative pregnancy rates following cryopreservation
      of all genetically transferable embryos after PGD, compared to fresh embryo transfer
      cumulative with frozen embryo transfer of genetically transferable embryos.The primary aim of
      the study is to assess the feasibility and effectiveness of segmentation in terms of
      pregnancy rates. The secondary aim is to assess the logistic advantage of segmentation in PGD
      cycles.

      Experimental questions

        1. Is the cumulative live birth rate rate of a single PGD treatment when all genetically
           transferable embryos are cryopreserved by vitrification prior to consecutive in utero
           transfer in unstimulated cycles, superior to PGD treatment with fresh embryo transfer
           cumulative with transfer of supernumerary cryopreserved embryos?

        2. Does the technique of segmentation allow better planning of DNA amplification and
           genetic analysis?

      Design The proposed design is a pragmatic, prospective randomised controlled trial
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative live birth rate of a single PGD treatment</measure>
    <time_frame>1 year</time_frame>
    <description>cumulative LBR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Clinical Pregnancy</condition>
  <condition>Live Birth</condition>
  <arm_group>
    <arm_group_label>freeze all embryos following PGD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>no fresh embryo transfer; elective cryopreservation of all embryos after PGD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elective fresh embryo transfer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>elective cryopreservation of available embryos after PGD</intervention_name>
    <description>no elective fresh embryo transfer; freeze all</description>
    <arm_group_label>freeze all embryos following PGD</arm_group_label>
    <other_name>freeze all embryos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD</intervention_name>
    <description>PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD</description>
    <arm_group_label>elective fresh embryo transfer</arm_group_label>
    <other_name>fresh ET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1st, 2nd or 3rd cycle of PGD in which embryo transfer was performed

          -  Indications for PGD: monogenic indications and X-linked disorders with a 25-50% risk
             of transmission and that are not associated with reduced ovarian response

          -  Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality
             within 6 months prior to randomisation.

          -  Regular menstrual cycles of 21-35 days, presumed to be ovulatory.

        Exclusion Criteria:

          -  POLYCYSTIC OVARIAN SYNDROME (Rotterdam criteria *)

             * At least two of the following three features: (i) Oligo- and/or anovulation (ii)
             Clinical and/or biochemical signs of hyperandrogenism (iii) Polycystic ovaries and
             exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting
             tumours, Cushing's syndrome)

          -  Poor responders (Bologna criteria **)

             * * At least two of the following three features: (i) Advanced maternal age (≥40
             years) or any other risk factor for poor ovarian response (POR); (ii) A previous POR
             (≤3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian
             reserve test (i.e. antral follicle count (AFC) 5-7 follicles, or anti-Mullerian
             hormone (AMH) 0.5-1.1 ng/ml).

          -  Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

          -  anticipated high response: AMH &gt;5.0 ng/ml or AFC &gt;20

          -  Endometriosis ≥ grade 3

          -  Age &gt; 40 years and 364 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>WILLEM MJA VERPOEST, MD PHD</last_name>
    <phone>+3224776699</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Reproductive Medicine UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>WILLEM MJA VERPOEST, MD PHD</last_name>
      <phone>+3224776699</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>VERPOEST WILLEM</investigator_full_name>
    <investigator_title>professor dr</investigator_title>
  </responsible_party>
  <keyword>preimplantation genetic diagnosis</keyword>
  <keyword>cryopreservation</keyword>
  <keyword>pregnancy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

